Year None202120202019201820172016 July 27, 2021 Medicenna Announces That Initiation of MDNA11 Phase 1/2 Study is on Track; Update to be Provided at the PropThink Digital Conference Go to July 14, 2021 Medicenna’s IL-2 Superkine Platform Featured in Peer-Reviewed Publication Demonstrating its Superiority and Ability to Reprogram the Tumor Microenvironment in Pancreatic Cancer Go to June 23, 2021 Medicenna Announces Submission of Clinical Trial Application in Australia for a Phase 1/2 Study of MDNA11 Go to May 28, 2021 Medicenna Reports Fiscal Year 2021 Financial Results and Operational Highlights Go to May 20, 2021 Medicenna to Announce Fiscal Year 2021 Financial Results and Operational Highlights on Friday, May 28, 2021 Go to May 12, 2021 Medicenna Appoints Immuno-Oncology Expert Dr. Mann Muhsin as Chief Medical Officer Go to Pagination Current page 1 Page 2 Page 3 Next page next › Last page last »
July 27, 2021 Medicenna Announces That Initiation of MDNA11 Phase 1/2 Study is on Track; Update to be Provided at the PropThink Digital Conference Go to
July 14, 2021 Medicenna’s IL-2 Superkine Platform Featured in Peer-Reviewed Publication Demonstrating its Superiority and Ability to Reprogram the Tumor Microenvironment in Pancreatic Cancer Go to
June 23, 2021 Medicenna Announces Submission of Clinical Trial Application in Australia for a Phase 1/2 Study of MDNA11 Go to
May 20, 2021 Medicenna to Announce Fiscal Year 2021 Financial Results and Operational Highlights on Friday, May 28, 2021 Go to
May 12, 2021 Medicenna Appoints Immuno-Oncology Expert Dr. Mann Muhsin as Chief Medical Officer Go to
